{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:37:57Z","timestamp":1786995477677,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020537","name":"Merck Sharp & Dohme (Australia) Pty Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1092160"],"award-info":[{"award-number":["APP1092160"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1117940"],"award-info":[{"award-number":["APP1117940"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.pathol.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T01:52:42Z","timestamp":1684720362000},"page":"663-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-2198","authenticated-orcid":false,"given":"Xenia","family":"Kostoulias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0109-0725","authenticated-orcid":false,"given":"Christina C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-6127","authenticated-orcid":false,"given":"Iain J.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Zisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis W.","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-2126","authenticated-orcid":false,"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.03.009_bib1","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2023.03.009_bib2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2023.03.009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105891","article-title":"Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications","volume":"55","author":"Maraolo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pathol.2023.03.009_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pathol.2023.03.009_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2023.03.009_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.pathol.2023.03.009_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2023.03.009_bib8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","article-title":"In\u00a0vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice","volume":"57","author":"Craig","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2023.03.009_bib9","series-title":"Thermo Scientific Sensititre Plate Guide for Antimicrobial Susceptibility Testing","year":"2018"},{"key":"10.1016\/j.pathol.2023.03.009_bib10","unstructured":"European Committee on Antimicrobial Susceptibility Testing. MIC and zone diameter distributions and ECOFFs. Cited 10 Jun 2022. http:\/\/www.eucast.org."},{"key":"10.1016\/j.pathol.2023.03.009_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pathol.2023.03.009_bib12","year":"2021"},{"key":"10.1016\/j.pathol.2023.03.009_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01633-17","article-title":"Performance of ceftolozane-tazobactam etest, MIC test strips, and disk diffusion compared to reference broth microdilution for beta-lactam-resistant Pseudomonas aeruginosia isolates","volume":"56","author":"Humphries","year":"2018","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.pathol.2023.03.009_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.diagmicrobio.2019.01.012","article-title":"Evaluation of in\u00a0vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"94","author":"Gherardi","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.pathol.2023.03.009_bib15","doi-asserted-by":"crossref","first-page":"dlab126","DOI":"10.1093\/jacamr\/dlab126","article-title":"Antimicrobial activity of ceftazidime\/avibactam, ceftolozane\/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients","volume":"3","author":"Sader","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.pathol.2023.03.009_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115302","article-title":"Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against US gram-negative bacterial surveillance isolates (2012-2018)","volume":"100","author":"Shortridge","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.pathol.2023.03.009_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02688-16","article-title":"In\u00a0vitro activity of ceftolozane-tazobactam against multidrug-resistant nonfermenting gram-negative bacilli isolated from patients with cystic fibrosis","volume":"61","author":"Grohs","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2023.03.009_bib18","doi-asserted-by":"crossref","first-page":"ofy158","DOI":"10.1093\/ofid\/ofy158","article-title":"In\u00a0vitro activity of ceftolozane\/tazobactam vs nonfermenting, gram-negative cystic fibrosis isolates","volume":"5","author":"Forrester","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.pathol.2023.03.009_bib19","series-title":"Zerbaxa Prescribing Information","year":"2022"},{"key":"10.1016\/j.pathol.2023.03.009_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.pathol.2023.03.009_bib21","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/jac\/dks246","article-title":"Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects","volume":"67","author":"Chandorkar","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2023.03.009_bib22","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2023.03.009_bib23","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2023.03.009_bib24","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/jac\/dkx221","article-title":"Determination of alternative ceftolozane\/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg\/L","volume":"72","author":"Natesan","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2023.03.009_bib25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10096-019-03573-4","article-title":"Continuous infusion of ceftolozane\/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa","volume":"38","author":"Pilmis","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pathol.2023.03.009_bib26","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/jac\/dkx253","article-title":"Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane\/tazobactam and comparison of different susceptibility testing methods","volume":"72","author":"Schaumburg","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2023.03.009_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01093-17","article-title":"Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"56","author":"Shields","year":"2018","journal-title":"J\u00a0Clin Microbiol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252300123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252300123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:30:48Z","timestamp":1758472248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003130252300123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S003130252300123X"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.03.009","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}